The Effect of Rosuvastatin on the Liver Enzyme of NMRI Mouse
Novelty in Biomedicine,
Vol. 10 No. 2 (2022),
9 May 2022
,
Page 101-106
https://doi.org/10.22037/nbm.v10i2.30759
Abstract
Background: Rosuvastatin is the newest statin family drug and acts as an HMG-CoA reductase inhibitor. Rosuvastatin can decrease the amount of cholesterol made by the liver and reduce the risk of heart disease. Since liver diseases are one of the significant causes of morbidity and mortality due to drugs toxicity, it is essential to check the liver’s function during widely used drugs such as rosuvastatin. Therefore, this study aimed to investigate the effect of rosuvastatin on the liver in the mature female NMRI mouse strain.
Materials and Methods: In this experimental study, 30 adult female NMRI strains (mice) at a mean weight of 25-30 grams were divided into five groups control, sham, and treatment groups. The mice of treated groups, including 1, 2, and 3, received rosuvastatin in doses of 10, 20, and 40 mg/Kg of body mass by oral gavage for 21 days. The mice in all groups were dissected after completing the gavage, their hearts were examined, and blood samples were obtained to measure liver enzymes. Then, the mice were sacrificed, and the liver tissue was subjected to antioxidant enzymes. The ELISA test measured the concentrations of the antioxidant and liver enzymes.
Results: The results showed that rosuvastatin decreased GPX, MDA, and FRAP with an increase in SOD, AST, and ALT (P<0.05).
Conclusion: It was concluded that high doses of rosuvastatin could damage the liver.
- Rosuvastatin, Liver, Antioxidant, Statin
How to Cite
References
Guo H, Lv H, Tang W, Chi J, Liu L, Xu F, et al. Rosuvastatin may modulate insulin signaling and inhibit atherogenesis beyond its plasma cholesterol-lowering effect in insulin-resistant mice. Cardiovascular drugs and therapy. 2012;26(5):375-82.
Cheng JW. Rosuvastatin in the management of hyperlipidemia. Clinical therapeutics. 2004;26(9):1368-87.
Zacharova A, Siller M, Spicakova A, Anzenbacherova E, Skottova N, Anzenbacher P, et al. Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats. Xenobiotica; the fate of foreign compounds in biological systems. 2012;42(8):731-6.
Panchavarthi C, Shankara UT, Pakanati V, Siddamshetty S, Konda JP, Kumar Gowlikar S. Efficacy of alternate day versus every day dosing of rosuvastatin in hyperlipidemia. International Journal of Basic & Clinical Pharmacology. 2017;5(5):2045-50.
Long SB, Blaha MJ, Blumenthal RS, Michos ED. Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly. Clin Interv Aging. 2011;6(1):27-35.
Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). The American journal of cardiology. 2003;92(2):152-60.
Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Annals of Internal Medicine. 2004;140(8):650-8.
Fong CW. Statins in therapy: understanding their hydrophilicity, lipophilicity, binding to 3-hydroxy-3-methylglutaryl-CoA reductase, ability to cross the blood blood-brainer and metabolic stability based on electrostatic molecular orbital studies. European Journal of medicinal chemistry. 2014;85:661-74.
Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovascular drug reviews. 2002;20(4):303-28.
Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundamental & clinical pharmacology. 2005;19(1):117-25.
McTaggart F. Comparative pharmacology of rosuvastatin. Atherosclerosis Supplements. 2003;4(1):9-14.
Guthrie RM, Martin DR. The safety of rosuvastatin: effects on renal and hepatic function. Expert opinion on drug safety. 2007;6(5):573-81.
Soltani M, Hajikhani B, Zamani S, Haghighi M, Hashemi A, Nasiri MJ, et al. Molecular characterization of Staphylococcus aureus strains isolated from hospitalized patients based on coagulase gene polymorphism analysis: High frequency of vancomycin-intermediate S. aureus and the emergence of coagulase type II in Iran. 2021;23:107..
Seyedjavadi SS, Razzaghi-Abyaneh M, Nasiri MJ, Hashemi A, Goudarzi H, Haghighi M, et al. Isolation and Chemical Characterization of an Alpha-Helical Peptide, Dendrocin-ZM1, Derived from Zataria multiflora Boiss with Potent Antibacterial Activity. 2022:1-11.
Leite GA, de Lima Rosa J, Sanabria M, Cavariani MM, Franci JA, Pinheiro PF, Kempinas WD. Delayed reproductive development in pubertal male rats exposed to the hypolipemiant agent rosuvastatin since prepuberty. Reproductive toxicology. 2014;44:93-103.
Reitman S. A colorimetric method for the determination of serum level of glutamate-oxaloacetate and pyruvate transaminases. Am J Clin Pathol. 1957;28:56-63.
Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. European journal of biochemistry. 1974;47(3):469-74.
Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. The Journal of laboratory and clinical medicine. 1967;70(1):158-69.
Buege JA, Aust SD. [30] Microsomal lipid peroxidation. Methods in enzymology. 52: Elsevier; 1978. p. 302-10.
Koracevic D, Koracevic G, Djordjevic V, Andrejevic S, Cosic V. Method for the measurement of antioxidant activity in human fluids. Journal of clinical pathology. 2001;54(5):356-61.
Sirtori CR. The pharmacology of statins. Pharmacological research. 2014;88:3-11.
Ramkumar S, Raghunath A, Raghunath S. Statin therapy: review of safety and potential side effects. Acta Cardiologica Sinica. 2016;32(6):631.
de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta‐analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2004;24(5):584-91.
Kasliwal R, Wilton LV, Cornelius V, Aurich-Barrera B, Shakir SA. Safety profile of rosuvastatin. Drug Safety. 2007;30(2):157-70.
Mohamed MF, Salameh OK, Saeed AA. Statin-induced rhabdomyolysis, acute kidney injury, and hepatitis leading to death. The American journal of case reports. 2019;20:709.
Rasooli A, Fatemi F, Akbarzadeh K, Dini S, Bahremand S. Synergistic protective activity of deuterium depleted water (DDW) and Satureja rechingeri essential oil on hepatic oxidative injuries induced by acetaminophen in rats. Journal of Essential Oil Bearing Plants. 2016;19(5):1086-101.
Chen GL, Hsiao FY, Dong YH, Shen LJ, Wu FLL. Statins and the risk of liver injury: a population‐based case‐control study. Pharmacoepidemiology and drug safety. 2014;23(7):719-25.
Yoon JH, Lee JM, Kim E, Okuaki T, Han JK. Quantitative liver function analysis: volumetric T1 mapping with fast multisection B1 inhomogeneity correction in hepatocyte-specific contrast-enhanced liver MR imaging. Radiology. 2017;282(2):408-17.
Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE, et al. Spectrum of statin hepatotoxicity: experience of the drug‐induced liver injury network. Hepatology. 2014;60(2):679-86.
Wang X, Wu Q, Liu A, Anadón A, Rodríguez J-L, Martínez-Larrañaga M-R, et al. Paracetamol: overdose-induced oxidative stress toxicity, metabolism, and protective effects of various compounds in vivo and in vitro. Drug metabolism reviews. 2017;49(4):395-437.
Sousa T, Afonso J, Carvalho F, Albino-Teixeira A. Lipid peroxidation and antioxidants in arterial hypertension. Lipid peroxidation. 2012:345-92.
Pal S, Ghosh M, Ghosh S, Bhattacharyya S, Sil PC. Atorvastatin induced hepatic oxidative stress and apoptotic damage via MAPKs, mitochondria, calpain and caspase12 dependent pathways. Food and Chemical Toxicology. 2015;83:36-47.
Farag M, Mohamed M, Youssef E. Assessment of hepatic function, oxidant/antioxidant status, and histopathological changes in rats treated with atorvastatin: effect of dose and acute intoxication with acetaminophen. Human & experimental toxicology. 2015;34(8):828-37.
Deo SH, Fisher JP, Vianna LC, Kim A, Chockalingam A, Zimmerman MC, et al. Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure. American Journal of Physiology-Heart and Circulatory Physiology. 2012;303(3):H377-H85.
Greig D, Alcaino H, Castro PF, Garcia L, Verdejo HE, Navarro M, et al. Xanthine-oxidase inhibitors and statins in chronic heart failure: effects on vascular and functional parameters. The Journal of Heart and Lung Transplantation. 2011;30(4):408-13.
Moon GJ, Kim SJ, Cho YH, Ryoo S, Bang OY. Antioxidant effects of statins in patients with atherosclerotic cerebrovascular disease. Journal of Clinical Neurology. 2014;10(2):140-7.
Dadkhah A, Fatemi F, Kazemnejad S, Rasmi Y, Ashrafi-Helan J, Allameh A. Differential effects of acetaminophen on enzymatic and non-enzymatic antioxidant factors and plasma total antioxidant capacity in developing and adult rats. Molecular and cellular Biochemistry. 2006;281(1-2):145.
Shin M-J, Chung N, Lee JH, Jang Y, Park E, Jeon K-I, et al. Effects of simvastatin on plasma antioxidant status and vitamins in hypercholesterolemic patients. International journal of cardiology. 2007;118(2):173-7.
Strzyżewski KW, Pioruńska-Stolzmann M, Majewski W, Kasprzak M, Strzyżewski W. Effect of surgical treatment on lipid peroxidation parameters and antioxidant status in the serum of patients with peripheral arterial disease. Disease markers. 2013;35(6):647-52.
Yazdanimehr S, Mohammadi MT. Protective effects of rosuvastatin against hyperglycemia-induced oxidative damage in the pancreas of streptozotocin-induced diabetic rats. Physiology and Pharmacology. 2018;22(1):19-27.
- Abstract Viewed: 180 times
- pdf Downloaded: 132 times